These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 27020620)

  • 1. Ten-year outcomes using low dose rate brachytherapy for localised prostate cancer: An update to the first Australian experience.
    Wilson C; Waterhouse D; Lane SE; Haworth A; Stanley J; Shannon T; Joseph D
    J Med Imaging Radiat Oncol; 2016 Aug; 60(4):531-8. PubMed ID: 27020620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer.
    Mitchell DM; Swindell R; Elliott T; Wylie JP; Taylor CM; Logue JP
    Radiother Oncol; 2008 Jul; 88(1):102-7. PubMed ID: 18453022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma.
    Ellis RJ; Vertocnik A; Kim E; Zhou H; Young B; Sodee B; Fu P; Beddar S; Colussi V; Spirnak JP; Dinchman KH; Resnick M; Kinsella TJ
    Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):362-70. PubMed ID: 12957246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation.
    Zelefsky MJ; Kuban DA; Levy LB; Potters L; Beyer DC; Blasko JC; Moran BJ; Ciezki JP; Zietman AL; Pisansky TM; Elshaikh M; Horwitz EM
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):327-33. PubMed ID: 17084558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Efficacy and Toxicity of Low-Dose-Rate ¹²⁵I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate Cancer.
    Kittel JA; Reddy CA; Smith KL; Stephans KL; Tendulkar RD; Ulchaker J; Angermeier K; Campbell S; Stephenson A; Klein EA; Wilkinson DA; Ciezki JP
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):884-93. PubMed ID: 25962627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
    Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
    Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
    Zelefsky MJ; Wallner KE; Ling CC; Raben A; Hollister T; Wolfe T; Grann A; Gaudin P; Fuks Z; Leibel SA
    J Clin Oncol; 1999 Feb; 17(2):517-22. PubMed ID: 10080594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective analysis after low-dose-rate prostate brachytherapy with permanent (125)I seed implant: clinical and dosimetric results in 70 patients.
    Chiumento C; Montagna A; Clemente S; Cozzolino M; Fusco V
    Tumori; 2011; 97(3):335-40. PubMed ID: 21789012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.
    Lawton CA; Yan Y; Lee WR; Gillin M; Firat S; Baikadi M; Crook J; Kuettel M; Morton G; Sandler H
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e795-801. PubMed ID: 22330999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of leeds 10-year single-center brachytherapy experience.
    Henry AM; Al-Qaisieh B; Gould K; Bownes P; Smith J; Carey B; Bottomley D; Ash D
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):50-6. PubMed ID: 20005453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (125)I monotherapy using D90 implant doses of 180 Gy or greater.
    Kao J; Stone NN; Lavaf A; Dumane V; Cesaretti JA; Stock RG
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):96-101. PubMed ID: 17980505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Dose and Quality Assurance in Early Prostate Cancer Treated with Low Dose Rate Brachytherapy as Monotherapy.
    Henry AM; Rodda SL; Mason M; Musunuru H; Al-Qaisieh B; Bownes P; Smith J; Franks K; Carey B; Bottomley D
    Clin Oncol (R Coll Radiol); 2015 Jul; 27(7):382-6. PubMed ID: 25805312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experience.
    Sylvester JE; Grimm PD; Wong J; Galbreath RW; Merrick G; Blasko JC
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):376-81. PubMed ID: 20864269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dose-response analysis of biochemical control outcomes after (125)I monotherapy for patients with favorable-risk prostate cancer.
    Shiraishi Y; Yorozu A; Ohashi T; Toya K; Saito S; Nishiyama T; Yagi Y; Shigematsu N
    Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1069-75. PubMed ID: 25539368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-year outcomes after iodine-125 seed brachytherapy for low-risk prostate cancer at three cancer centres in the UK.
    Dickinson PD; Malik J; Mandall P; Swindell R; Bottomley D; Hoskin P; Logue JP; Wylie JP
    BJU Int; 2014 May; 113(5):748-53. PubMed ID: 24053230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Manual vs. automated implantation of seeds in prostate brachytherapy: Oncologic results from a single-center study.
    Thomas L; Chemin A; Leduc N; Belhomme S; Rich E; Lasbareilles O; Giraud A; Descat E; Roubaud G; Sargos P
    Brachytherapy; 2018; 17(1):214-220. PubMed ID: 29102738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.
    Gondi V; Deutsch I; Mansukhani M; O'Toole KM; Shah JN; Schiff PB; Katz AE; Benson MC; Goluboff ET; Ennis RD
    Urology; 2007 Mar; 69(3):541-6. PubMed ID: 17382161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical disease-free survival following 125I prostate implantation.
    Beyer DC; Priestley JB
    Int J Radiat Oncol Biol Phys; 1997 Feb; 37(3):559-63. PubMed ID: 9112453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Favourable long-term outcomes with brachytherapy-based regimens in men ≤60 years with clinically localized prostate cancer.
    Kollmeier MA; Fidaleo A; Pei X; Cohen G; Zaider M; Mo Q; Cox B; Yamada Y; Zelefsky MJ
    BJU Int; 2013 Jun; 111(8):1231-6. PubMed ID: 23551568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10 years of follow-up with localized prostate cancer treated by permanent iodine implants.
    Prada PJ; Juan G; González-Suárez H; Fernández J; Jimenez I; Amón J; Cepeda M
    BJU Int; 2010 Jul; 106(1):32-6. PubMed ID: 20067460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.